Form 4: Atossa Therapeutics CEO Steven Quay Acquires 1,795,100 Stock Options
SEC Form 4 Filing
Atossa Therapeutics' CEO, Steven Quay, was granted 1,795,100 stock options on June 27, 2024, exercisable at $1.05 per share.
Summary
- On June 27, 2024, Steven C. Quay, the President and CEO of Atossa Therapeutics, acquired 1,795,100 stock options.
- The exercise price for these options is $1.05 per share, which was the closing stock price on June 26, 2024.
- The options vest quarterly over 24 months, contingent upon Quay's continued service to Atossa Therapeutics.
- The options expire on June 27, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued service and contribution from the CEO over the next 24 months.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant and the vesting schedule are typical for a CEO of a company with Atossa's market capitalization.
- Comparable companies such as Clovis Oncology and Puma Biotechnology also utilize stock options as part of their executive compensation strategy.
Stakeholder Impact
- Shareholders: The grant of options aligns the CEO's interests with increasing shareholder value.
- Employees: The grant of options to the CEO can boost employee morale by demonstrating confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Closing stock price of $1.05 used to determine option exercise price. |
| 06/27/2024 | Date of transaction: Steven Quay acquired 1,795,100 stock options. |
| 06/27/2024 | Options issued at approximately 9:30 a.m. (ET). |
| 06/27/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.